EP0609306A1 - Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors - Google Patents
Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptorsInfo
- Publication number
- EP0609306A1 EP0609306A1 EP92921626A EP92921626A EP0609306A1 EP 0609306 A1 EP0609306 A1 EP 0609306A1 EP 92921626 A EP92921626 A EP 92921626A EP 92921626 A EP92921626 A EP 92921626A EP 0609306 A1 EP0609306 A1 EP 0609306A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzodiazepin
- dihydro
- oxo
- urea
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000005557 antagonist Substances 0.000 title abstract description 16
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 title description 9
- 102000052874 Gastrin receptors Human genes 0.000 title description 8
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title description 8
- 102000004859 Cholecystokinin Receptors Human genes 0.000 title description 7
- 108090001085 Cholecystokinin Receptors Proteins 0.000 title description 7
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title description 3
- 229940107137 cholecystokinin Drugs 0.000 title description 3
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 182
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 42
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 108010052343 Gastrins Proteins 0.000 claims abstract description 25
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 239000000651 prodrug Substances 0.000 claims abstract description 14
- 229940002612 prodrug Drugs 0.000 claims abstract description 14
- 125000001424 substituent group Chemical group 0.000 claims abstract description 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 9
- 102100021022 Gastrin Human genes 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims description 52
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 50
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 43
- 239000004202 carbamide Substances 0.000 claims description 29
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- VEYIMQVTPXPUHA-UHFFFAOYSA-N pyromeconic acid Natural products OC1=COC=CC1=O VEYIMQVTPXPUHA-UHFFFAOYSA-N 0.000 claims description 16
- -1 imidazolyl Chemical group 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 14
- UVQVMNIYFXZXCI-UHFFFAOYSA-N (3-methylphenyl)urea Chemical compound CC1=CC=CC(NC(N)=O)=C1 UVQVMNIYFXZXCI-UHFFFAOYSA-N 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 150000003536 tetrazoles Chemical group 0.000 claims description 7
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- BICMJXXRUNJIDJ-UHFFFAOYSA-N (3-ethylphenyl)urea Chemical compound CCC1=CC=CC(NC(N)=O)=C1 BICMJXXRUNJIDJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- GPCDGGKVBPVZCT-UHFFFAOYSA-N 1,1-difluorocyclopropane Chemical compound FC1(F)CC1 GPCDGGKVBPVZCT-UHFFFAOYSA-N 0.000 claims description 4
- DVFMMTZLRLVQKX-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-3-[5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound N=1C(NC(=O)NC=2C=C3CCCC3=CC=2)C(=O)N(CCC)C2=CC=CC=C2C=1N1CCN(C)CC1 DVFMMTZLRLVQKX-UHFFFAOYSA-N 0.000 claims description 4
- ZMUBIYUMHFIWON-UHFFFAOYSA-N 1-[5-(azepan-1-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea Chemical compound O=C1N(C)C2=CC=CC=C2C(N2CCCCCC2)=NC1NC(=O)NC1=CC=CC(C)=C1 ZMUBIYUMHFIWON-UHFFFAOYSA-N 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- NRHDCQLCSOWVTF-UHFFFAOYSA-N azonane Chemical compound C1CCCCNCCC1 NRHDCQLCSOWVTF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- AUCCGRMNONDKLE-UHFFFAOYSA-N 1-(3-ethylphenyl)-3-[5-(4-methylpiperazin-1-yl)-1-(2-methylpropyl)-2-oxo-3h-1,4-benzodiazepin-3-yl]urea Chemical compound CCC1=CC=CC(NC(=O)NC2C(N(CC(C)C)C3=CC=CC=C3C(N3CCN(C)CC3)=N2)=O)=C1 AUCCGRMNONDKLE-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 claims description 3
- DMSHKWHLXNDUST-UHFFFAOYSA-N (4-methylphenyl)urea Chemical compound CC1=CC=C(NC(N)=O)C=C1 DMSHKWHLXNDUST-UHFFFAOYSA-N 0.000 claims description 2
- LZAGGCJFDYFTTO-UHFFFAOYSA-N 1-[3-(dimethylamino)phenyl]-3-[5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound O=C1N(CCC)C2=CC=CC=C2C(N2CCN(C)CC2)=NC1NC(=O)NC1=CC=CC(N(C)C)=C1 LZAGGCJFDYFTTO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- WDHPVLQWHRHMEY-UHFFFAOYSA-N (3-methoxyphenyl)urea Chemical compound COC1=CC=CC(NC(N)=O)=C1 WDHPVLQWHRHMEY-UHFFFAOYSA-N 0.000 claims 2
- QVESWSYUIJCCIV-UHFFFAOYSA-N 1-(3-methylphenyl)-3-(2-oxo-1-propyl-5-thiomorpholin-4-yl-3h-1,4-benzodiazepin-3-yl)urea Chemical compound O=C1N(CCC)C2=CC=CC=C2C(N2CCSCC2)=NC1NC(=O)NC1=CC=CC(C)=C1 QVESWSYUIJCCIV-UHFFFAOYSA-N 0.000 claims 2
- HIDXDIXMVZDVNO-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-3h-1,4-benzodiazepin-3-yl]urea Chemical compound O=C1N(CCC)C2=CC=CC=C2C(N2CCN(C)CC2)=NC1NC(=O)NC1=CC=CC(C)=C1 HIDXDIXMVZDVNO-UHFFFAOYSA-N 0.000 claims 2
- UBXROGCRMRGBDC-UHFFFAOYSA-N 1-[5-(azepan-1-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(2,3-dihydro-1h-inden-5-yl)urea Chemical compound N=1C(NC(=O)NC=2C=C3CCCC3=CC=2)C(=O)N(C)C2=CC=CC=C2C=1N1CCCCCC1 UBXROGCRMRGBDC-UHFFFAOYSA-N 0.000 claims 2
- WUOFTQDQVXBVFZ-UHFFFAOYSA-N 1-[5-(azepan-1-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(3-ethylphenyl)urea Chemical compound CCC1=CC=CC(NC(=O)NC2C(N(C)C3=CC=CC=C3C(N3CCCCCC3)=N2)=O)=C1 WUOFTQDQVXBVFZ-UHFFFAOYSA-N 0.000 claims 2
- IPRCBIWIPMJXIK-UHFFFAOYSA-N (3-hydroxyphenyl)urea Chemical compound NC(=O)NC1=CC=CC(O)=C1 IPRCBIWIPMJXIK-UHFFFAOYSA-N 0.000 claims 1
- RECCURWJDVZHIH-UHFFFAOYSA-N (4-chlorophenyl)urea Chemical compound NC(=O)NC1=CC=C(Cl)C=C1 RECCURWJDVZHIH-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- VNWYFYRRSVFBRL-UHFFFAOYSA-N [3-(1-methyltetrazol-5-yl)phenyl]urea Chemical compound CN1N=NN=C1C1=CC=CC(NC(N)=O)=C1 VNWYFYRRSVFBRL-UHFFFAOYSA-N 0.000 claims 1
- FPKFSFBDSGXAAR-UHFFFAOYSA-N [3-(2-methyltetrazol-5-yl)phenyl]urea Chemical compound CN1N=NC(C=2C=C(NC(N)=O)C=CC=2)=N1 FPKFSFBDSGXAAR-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 342
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 324
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 174
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 152
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 92
- 239000000377 silicon dioxide Substances 0.000 description 76
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 59
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 52
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 45
- 239000007787 solid Substances 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 101710089098 Cholecystokinins Proteins 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 229910001868 water Inorganic materials 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 229960004132 diethyl ether Drugs 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 229910052938 sodium sulfate Inorganic materials 0.000 description 24
- 235000011152 sodium sulphate Nutrition 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 102400000921 Gastrin Human genes 0.000 description 21
- 229960000583 acetic acid Drugs 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 239000012458 free base Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 17
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 150000001412 amines Chemical class 0.000 description 14
- 239000006071 cream Substances 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 238000010609 cell counting kit-8 assay Methods 0.000 description 12
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000012362 glacial acetic acid Substances 0.000 description 11
- JONDAZYPJRLYGG-SNVBAGLBSA-N (2S)-2-benzamido-4-methyl-3,3-dinitropentanoic acid Chemical compound [N+](=O)([O-])C([C@H](NC(C1=CC=CC=C1)=O)C(=O)O)(C(C)C)[N+](=O)[O-] JONDAZYPJRLYGG-SNVBAGLBSA-N 0.000 description 10
- VTBGAPOTKXFPFB-UHFFFAOYSA-N 3-amino-5-(azepan-1-yl)-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(C)C2=CC=CC=C2C=1N1CCCCCC1 VTBGAPOTKXFPFB-UHFFFAOYSA-N 0.000 description 10
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229940049706 benzodiazepine Drugs 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- CPPGZWWUPFWALU-UHFFFAOYSA-N 1-isocyanato-3-methylbenzene Chemical compound CC1=CC=CC(N=C=O)=C1 CPPGZWWUPFWALU-UHFFFAOYSA-N 0.000 description 6
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000001557 benzodiazepines Chemical class 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 6
- DNFZCDLEGMEKMI-UHFFFAOYSA-N 1-ethyl-3-isocyanatobenzene Chemical compound CCC1=CC=CC(N=C=O)=C1 DNFZCDLEGMEKMI-UHFFFAOYSA-N 0.000 description 5
- DOZCLWLSKOSWDB-UHFFFAOYSA-N 3-amino-5-(4-methylpiperazin-1-yl)-1-propyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(CCC)C2=CC=CC=C2C=1N1CCN(C)CC1 DOZCLWLSKOSWDB-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 108010087230 Sincalide Proteins 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 150000002923 oximes Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 5
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 4
- NFUUHITZCXMSBH-UHFFFAOYSA-N 3-amino-1-methyl-5-(4-methylpiperazin-1-yl)-3h-1,4-benzodiazepin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CN(C)CCN1C1=NC(N)C(=O)N(C)C2=CC=CC=C12 NFUUHITZCXMSBH-UHFFFAOYSA-N 0.000 description 4
- ITQGHVCECASRNT-UHFFFAOYSA-N 3-amino-5-(4-methylpiperazin-1-yl)-1-propyl-3h-1,4-benzodiazepin-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C(N)C(=O)N(CCC)C2=CC=CC=C2C=1N1CCN(C)CC1 ITQGHVCECASRNT-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 208000019906 panic disease Diseases 0.000 description 4
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- SXJYSIBLFGQAND-UHFFFAOYSA-N 1-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(N=C=O)=C1 SXJYSIBLFGQAND-UHFFFAOYSA-N 0.000 description 3
- LEWZOBYWGWKNCK-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-amine Chemical compound NC1=CC=C2CCCC2=C1 LEWZOBYWGWKNCK-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- NHHGYZUVVIVJSO-UHFFFAOYSA-N 2-methyl-5-(3-nitrophenyl)tetrazole Chemical compound CN1N=NC(C=2C=C(C=CC=2)[N+]([O-])=O)=N1 NHHGYZUVVIVJSO-UHFFFAOYSA-N 0.000 description 3
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 3
- IPWGAPCYYMTTLT-UHFFFAOYSA-N 3-propylaniline Chemical compound CCCC1=CC=CC(N)=C1 IPWGAPCYYMTTLT-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 206010027646 Miosis Diseases 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000003754 cholecystokinin receptor blocking agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 201000000052 gastrinoma Diseases 0.000 description 3
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000003547 miosis Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- UHCPCZKBZOSOLC-UHFFFAOYSA-N 1-ethyl-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)N(CC)C2=C1 UHCPCZKBZOSOLC-UHFFFAOYSA-N 0.000 description 2
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 2
- ZWXDYSNVJMNJQS-UHFFFAOYSA-N 1-methyl-2,3-dihydroindol-6-amine Chemical compound C1=C(N)C=C2N(C)CCC2=C1 ZWXDYSNVJMNJQS-UHFFFAOYSA-N 0.000 description 2
- HRRUUKMOEWHYKX-UHFFFAOYSA-N 1-methyl-6-nitro-2,3-dihydroindole Chemical compound C1=C([N+]([O-])=O)C=C2N(C)CCC2=C1 HRRUUKMOEWHYKX-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- VBBAMBIEAFCKCS-UHFFFAOYSA-N 3-(1-methyltetrazol-5-yl)aniline Chemical compound CN1N=NN=C1C1=CC=CC(N)=C1 VBBAMBIEAFCKCS-UHFFFAOYSA-N 0.000 description 2
- DWALVYAEZSBQAZ-UHFFFAOYSA-N 3-amino-1-methyl-5-(4-methylpiperazin-1-yl)-3h-1,4-benzodiazepin-2-one Chemical compound C1CN(C)CCN1C1=NC(N)C(=O)N(C)C2=CC=CC=C12 DWALVYAEZSBQAZ-UHFFFAOYSA-N 0.000 description 2
- HHSBHVJQXZLIRW-UHFFFAOYSA-N 3-n,3-n-dimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(N)=C1 HHSBHVJQXZLIRW-UHFFFAOYSA-N 0.000 description 2
- OLIJZIJVURIOSB-UHFFFAOYSA-N 3-nitroprop-1-enylbenzene Chemical compound [O-][N+](=O)CC=CC1=CC=CC=C1 OLIJZIJVURIOSB-UHFFFAOYSA-N 0.000 description 2
- ZJFFBXHGOXPKCP-UHFFFAOYSA-N 5-(3-nitrophenyl)-2h-tetrazole Chemical compound [O-][N+](=O)C1=CC=CC(C2=NNN=N2)=C1 ZJFFBXHGOXPKCP-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- OEJAFAYRENHHHE-UHFFFAOYSA-N [6-(3-aminophenyl)-4-oxopyran-3-yl] acetate Chemical compound O=C1C(OC(=O)C)=COC(C=2C=C(N)C=CC=2)=C1 OEJAFAYRENHHHE-UHFFFAOYSA-N 0.000 description 2
- VYWQTJWGWLKBQA-UHFFFAOYSA-N [amino(hydroxy)methylidene]azanium;chloride Chemical compound Cl.NC(N)=O VYWQTJWGWLKBQA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002513 isocyanates Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- XCMVSUPUUQDGTL-UHFFFAOYSA-N methyl 2-(2-methylpropylamino)benzoate Chemical compound COC(=O)C1=CC=CC=C1NCC(C)C XCMVSUPUUQDGTL-UHFFFAOYSA-N 0.000 description 2
- GVOWHGSUZUUUDR-UHFFFAOYSA-N methyl N-methylanthranilate Chemical compound CNC1=CC=CC=C1C(=O)OC GVOWHGSUZUUUDR-UHFFFAOYSA-N 0.000 description 2
- 229940102398 methyl anthranilate Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- DKWDGIRXGDSOST-UHFFFAOYSA-N n,n-dimethyl-3-nitrobenzamide Chemical compound CN(C)C(=O)C1=CC=CC([N+]([O-])=O)=C1 DKWDGIRXGDSOST-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000618 neurotoxin Toxicity 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FNJQMZSSPJYRSD-UHFFFAOYSA-N (1-methoxy-3-oxobut-1-en-2-yl) acetate Chemical compound COC=C(C(C)=O)OC(C)=O FNJQMZSSPJYRSD-UHFFFAOYSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- NJATWJUOMHPPHK-UHFFFAOYSA-N 1-(3-aminophenyl)-3-methylurea Chemical compound CNC(=O)NC1=CC=CC(N)=C1 NJATWJUOMHPPHK-UHFFFAOYSA-N 0.000 description 1
- NCKXJUULKKCLOB-UHFFFAOYSA-N 1-(3-methylphenyl)-3-(2-oxo-1-propyl-5-thiomorpholin-4-yl-3h-1,4-benzodiazepin-3-yl)urea;hydrochloride Chemical compound Cl.O=C1N(CCC)C2=CC=CC=C2C(N2CCSCC2)=NC1NC(=O)NC1=CC=CC(C)=C1 NCKXJUULKKCLOB-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- MRAFJAIYMVKTKN-UHFFFAOYSA-N 1-[5-(azepan-1-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl]-1-(3-methylphenyl)urea Chemical compound O=C1N(C)C2=CC=CC=C2C(N2CCCCCC2)=NC1N(C(N)=O)C1=CC=CC(C)=C1 MRAFJAIYMVKTKN-UHFFFAOYSA-N 0.000 description 1
- RRJNRUBZJNPNQZ-UHFFFAOYSA-N 1-[5-(azepan-1-yl)-1-methyl-2-oxo-3h-1,4-benzodiazepin-3-yl]-3-(2,3-dihydro-1h-inden-5-yl)urea;hydrochloride Chemical compound Cl.N=1C(NC(=O)NC=2C=C3CCCC3=CC=2)C(=O)N(C)C2=CC=CC=C2C=1N1CCCCCC1 RRJNRUBZJNPNQZ-UHFFFAOYSA-N 0.000 description 1
- ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 1
- RIKWVZGZRYDACA-UHFFFAOYSA-N 1-fluoro-3-isocyanatobenzene Chemical compound FC1=CC=CC(N=C=O)=C1 RIKWVZGZRYDACA-UHFFFAOYSA-N 0.000 description 1
- YMKOXSFWJLLVPK-UHFFFAOYSA-N 1-methyl-3-[3-[[5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-3h-1,4-benzodiazepin-3-yl]carbamoylamino]phenyl]urea Chemical compound O=C1N(CCC)C2=CC=CC=C2C(N2CCN(C)CC2)=NC1NC(=O)NC1=CC=CC(NC(=O)NC)=C1 YMKOXSFWJLLVPK-UHFFFAOYSA-N 0.000 description 1
- QKAFKWWKUGJFIJ-UHFFFAOYSA-N 1-methyl-5-(3-nitrophenyl)tetrazole Chemical compound CN1N=NN=C1C1=CC=CC([N+]([O-])=O)=C1 QKAFKWWKUGJFIJ-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- NBUUUJWWOARGNW-UHFFFAOYSA-N 2-amino-5-methylbenzoic acid Chemical compound CC1=CC=C(N)C(C(O)=O)=C1 NBUUUJWWOARGNW-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- UYAVRNZBWKONLN-UHFFFAOYSA-N 2-chloro-5-hydroxypyran-4-one Chemical group OC1=COC(Cl)=CC1=O UYAVRNZBWKONLN-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- MQGHNXCWKDXJLP-UHFFFAOYSA-N 3-(2-methyltetrazol-5-yl)aniline Chemical compound CN1N=NC(C=2C=C(N)C=CC=2)=N1 MQGHNXCWKDXJLP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FQLHACLNTQGSJE-UHFFFAOYSA-N 3-amino-1-methyl-5-piperidin-1-yl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(C)C2=CC=CC=C2C=1N1CCCCC1 FQLHACLNTQGSJE-UHFFFAOYSA-N 0.000 description 1
- JKLBVLUUBRBNHG-UHFFFAOYSA-N 3-amino-1-methyl-5-thiomorpholin-4-yl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(C)C2=CC=CC=C2C=1N1CCSCC1 JKLBVLUUBRBNHG-UHFFFAOYSA-N 0.000 description 1
- INBXPQMXHHEEPY-UHFFFAOYSA-N 3-amino-1-propyl-5-thiomorpholin-4-yl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(CCC)C2=CC=CC=C2C=1N1CCSCC1 INBXPQMXHHEEPY-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 1
- RUSAWEHOGCWOPG-UHFFFAOYSA-N 3-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC(C#N)=C1 RUSAWEHOGCWOPG-UHFFFAOYSA-N 0.000 description 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- UEALKTCRMBVTFN-UHFFFAOYSA-N 4-nitroanthranilic acid Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(O)=O UEALKTCRMBVTFN-UHFFFAOYSA-N 0.000 description 1
- WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical compound CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 1
- MGYGFNQQGAQEON-UHFFFAOYSA-N 4-tolyl isocyanate Chemical compound CC1=CC=C(N=C=O)C=C1 MGYGFNQQGAQEON-UHFFFAOYSA-N 0.000 description 1
- FRNNIVRDFDEWPU-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)-1-(2-methylpropyl)-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC(C)C)C2=CC=CC=C2C=1N1CCN(C)CC1 FRNNIVRDFDEWPU-UHFFFAOYSA-N 0.000 description 1
- JVCFABMMJREDDY-UHFFFAOYSA-N 5-(azepan-1-yl)-1-propyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CCC)C2=CC=CC=C2C=1N1CCCCCC1 JVCFABMMJREDDY-UHFFFAOYSA-N 0.000 description 1
- BKAQPHNACKQMGI-UHFFFAOYSA-N 5-chloro-1-methyl-3h-1,4-benzodiazepin-2-one;hydrochloride Chemical compound Cl.ClC1=NCC(=O)N(C)C2=CC=CC=C21 BKAQPHNACKQMGI-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- LTNYDSMDSLOMSM-UHFFFAOYSA-N 6-nitro-2,3-dihydro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2CCNC2=C1 LTNYDSMDSLOMSM-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010002758 Anticipatory anxiety Diseases 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940122623 CCK receptor antagonist Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 108010089335 Cholecystokinin A Receptor Proteins 0.000 description 1
- 102100034927 Cholecystokinin receptor type A Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 102100036016 Gastrin/cholecystokinin type B receptor Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- PFOJUYNUMISXLI-UHFFFAOYSA-N [6-(3-nitrophenyl)-4-oxopyran-3-yl] acetate Chemical compound O=C1C(OC(=O)C)=COC(C=2C=C(C=CC=2)[N+]([O-])=O)=C1 PFOJUYNUMISXLI-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- MGVAEBQKTKBVOR-UHFFFAOYSA-N acetic acid;3-amino-5-(4-methylpiperazin-1-yl)-1-propyl-3h-1,4-benzodiazepin-2-one Chemical compound CC(O)=O.N=1C(N)C(=O)N(CCC)C2=CC=CC=C2C=1N1CCN(C)CC1 MGVAEBQKTKBVOR-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- YDLSUFFXJYEVHW-UHFFFAOYSA-N azonan-2-one Chemical compound O=C1CCCCCCCN1 YDLSUFFXJYEVHW-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- QFLBZJPOIZFFJQ-UHFFFAOYSA-N cholecystokinin 33 Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CCSC)C(=O)NC(CC(O)=O)C(=O)NC(CC=1C=CC=CC=1)C(N)=O)NC(=O)CNC(=O)C(CCSC)NC(=O)C(C=1C=CC(OS(O)(=O)=O)=CC=1)NC(=O)C(CC(O)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(CO)NC(=O)C1N(CCC1)C(=O)C(CC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(NC(=O)C(CO)NC(=O)C(CCSC)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(CO)NC(=O)C1N(CCC1)C(=O)C(C)NC(=O)C(N)CCCCN)C(C)CC)C(C)C)CC1=CNC=N1 QFLBZJPOIZFFJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000004600 colonic motility Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- JHYNXXDQQHTCHJ-UHFFFAOYSA-M ethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CC)C1=CC=CC=C1 JHYNXXDQQHTCHJ-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- ZASLZWMSIYHFCF-UHFFFAOYSA-N methyl 2-[(2-bromoacetyl)-methylamino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N(C)C(=O)CBr ZASLZWMSIYHFCF-UHFFFAOYSA-N 0.000 description 1
- QRSQCUBYPABFKB-UHFFFAOYSA-N methyl 2-[(2-bromoacetyl)-methylamino]benzoate;sodium Chemical compound [Na].COC(=O)C1=CC=CC=C1N(C)C(=O)CBr QRSQCUBYPABFKB-UHFFFAOYSA-N 0.000 description 1
- VAQBJVZNPBNHGC-UHFFFAOYSA-N methyl 2-amino-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C=C1N VAQBJVZNPBNHGC-UHFFFAOYSA-N 0.000 description 1
- VGURYVWLCVIMTF-UHFFFAOYSA-N methyl 2-amino-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C=C1N VGURYVWLCVIMTF-UHFFFAOYSA-N 0.000 description 1
- MDHYFUPTSWXVIA-UHFFFAOYSA-N methyl 2-amino-5-methylbenzoate Chemical compound COC(=O)C1=CC(C)=CC=C1N MDHYFUPTSWXVIA-UHFFFAOYSA-N 0.000 description 1
- AJOIFLDYDRTTFM-UHFFFAOYSA-N methyl 4-nitro-2-(propylamino)benzoate Chemical compound CCCNC1=CC([N+]([O-])=O)=CC=C1C(=O)OC AJOIFLDYDRTTFM-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- PEMGGJDINLGTON-UHFFFAOYSA-N n-(3-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(N)=C1 PEMGGJDINLGTON-UHFFFAOYSA-N 0.000 description 1
- GSMPSKWDIFSIAR-UHFFFAOYSA-N n-cyclohexyl-1-(4-nitrophenyl)methanimine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=NC1CCCCC1 GSMPSKWDIFSIAR-UHFFFAOYSA-N 0.000 description 1
- MEHSMNJKCAVTNH-UHFFFAOYSA-N n-ethyl-3-nitrobenzamide Chemical compound CCNC(=O)C1=CC=CC([N+]([O-])=O)=C1 MEHSMNJKCAVTNH-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000631 nonopiate Effects 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- LRTFPLFDLJYEKT-UHFFFAOYSA-N para-isopropylaniline Chemical compound CC(C)C1=CC=C(N)C=C1 LRTFPLFDLJYEKT-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- RYYNGWLOYLRZLK-RBUKOAKNSA-N pf03814735 Chemical compound C1([C@H]2CC[C@@H](C1=CC=1)N2C(=O)CNC(=O)C)=CC=1NC(N=1)=NC=C(C(F)(F)F)C=1NC1CCC1 RYYNGWLOYLRZLK-RBUKOAKNSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to benzodiazepine compounds which are useful as antagonists of cholecystokinin and gastrin receptors.
- Cholecystokinins (CCK) and gastrin are structurally related peptides which exist in gastrointestinal tissue and in the central nervous system (see, V. Mutt,
- Gastrointestinal Hormones G.B.J. Green, Ed., Raven Press, N.Y., p.169 and G. Nission, ibid. p.127).
- Cholecystokinins include CCK-33, a neuropeptide of thirty-three amino acids in its originally isolated form (see. Mutt and Jorpes, Biochem. J. 125. 678 (1971)), its carboxylterminal octapeptide, CCK-8 (also a naturally-occurring neuropeptide and the minimum fully active sequence), and 39- and 12-amino acid forms. Gastrin occurs in 34-, 17- and 14-amino acid forms, with the minimum active sequence being the C-terminal
- Trp-Met-Asp-Phe-NH 2 which is the common structural element shared by both CCK and gastrin.
- CCKs are believed to be physiological satiety hormones, thereby possibly playing an important role in appetite regulation (G. P. Smith, Eating and Its
- gastrin The primary role of gastrin, on the other hand, appears to be stimulation of the secretion of water and electrolytes from the stomach and, as such, is involved in control of gastric acid and pepsin secretion. Other physiological effects of gastrin then include increased mucosal blood flow and increased antral motility. Rat studies have shown that gastrin has a positive trophic effect on the gastric mucosa, as evidenced by increased DNA, RNA and protein synthesis.
- CCK-A and CCK-B cholecystokinin receptors
- CCK and gastrin receptor antagonists have been disclosed for preventing and treating CCK-related and/or gastrin related disorders of the gastrointestinal (GI) and central nervous (CNS) systems of animals, especially mammals, and more especially those of humans.
- GI gastrointestinal
- CNS central nervous
- antagonists also tend to have affinity for both CCK-B receptors and gastrin receptors.
- Other antagonists have activity at the CCK-A subtype.
- Selective CCK antagonists are themselves useful in treating CCK-related disorders of appetite regulatory systems of animals as well as in potentiating and
- CCK-B and CCK-A antagonists have also been shown to have a direct analgesic effect [M.F. O'Neill et al., Brain Research, 534 287 (1990)].
- Selective CCK and gastrin antagonists are useful in the modulation of behaviour mediated by dopaminergic and serotonergic neuronal systems and thus have utility in the treatment of schizophrenia and depression (Rasmussen et. al., 1991, Eur. J. Pharmacol., 209, 135-138; Woodruff et. al., 1991, Neuropeptides.
- CCK antagonists are useful anxiolytic agents and can be used in the treatment of panic and anxiety disorders.
- CCK has been reported to evoke the release of stress hormones such as adrenocorticotrophic hormone, ⁇ -endorphin, vasopressin and oxytocin, CCK may function as a mediator of responses to stress and as part of the arousal system.
- stress hormones such as adrenocorticotrophic hormone, ⁇ -endorphin, vasopressin and oxytocin
- CCK-A receptors are now known to be present in a number of areas of the CNS and may be involved in modulating any of the above.
- CCK may be involved in the regulation of stress and its relationship with drug abuse e.g. alleviation of the benzodiazepine withdrawal syndrome (Singh et. al., 1992, Br. J. Pharmacol., 105, 8-10%) and neuroadaptive
- CCK antagonists may also be effective in neuroprotection.
- CCK receptor antagonists have been found to inhibit the contractile effects of CCK on iris sphincter and ciliary muscles of monkey and human eyes (Eur. J.
- European patent application no. 0 167 919 discloses benzodiazepine CCK and gastrin antagonists substituted in the 3-position by, inter alia, a phenyl urea and at the 5-position by an optionally substituted phenyl or pyridyl group.
- benzodiazepine derivatives optionally substituted at the 3-position by C 1-4 alkyl or phenyl and substituted at the 5-position by a 3 to 8-membered azacycle, bound through nitrogen, which azacycle may optionally contain a further O, S or N atom.
- the compounds are said to have CNS activity. There is no suggestion of a nitrogen-containing substitutuent at the 3-position. Nor is there any suggestion that the disclosed compounds are
- the present invention provides benzodiazepine compounds of formula (I):
- X represents O, S, NR 4 or CH 2 where R 4 represents H, C 1-4 alkyl, CO 2 R a , COR a or SO 2 R a where R a is C 1-6 alkyl, optionally substituted phenyl or benzyl optionally substituted in the phenyl ring by one or more
- substituents where the phenyl substituents are selected from C 1-4 alkyl, C 1-4 alkyl , halo and trifluoromethyl;
- R 1 represents H, C 1-6 alkyl, C 3-7 cycloalkyl
- R 2 represents a phenyl group optionally substituted by one or more substituents selected from C 1-6 alkyl, halo, hydroxy, OR 5 (where R 5 is as previously defined), (CH 2 ) q -tetrazolyl optionally substituted in the tetrazole ring by C 1-4 alkyl, (CH 2 ) q -imidazolyl, (CH 2 )q-triazolyl (where q is 0, 1, 2 or 3), 5-hydroxy-4-pyrone, NR 6 R 7 , NR 9 COR 5 , NR 9 CONR 9' R 5 (where R 9 and R 9' are each
- R 5 independently H or C 1-4 alkyl and R 5 is as previously defined), CONR 6 R 7 (where R 6 and R 7 are as previously defined), SO(C 1-4 alkyl), SO2 (C 1-4 alkyl), trifluoromethyl, CONHSO 2 R 8 , SO 2 NHCOR 8 (where R 8 is C 1-6 alkyl, optionally substituted aryl, 2,2-difluorocyclopropane or
- R 2 represents a group
- W represents CH 2 or NR 9 , where R 9 is as previously defined, and W 1 represents CH 2 , or W and W 1 each
- R 3 represents C 1-6 alkyl, halo or NR 6 R 7 , where R 6 and R 7 are as previously defined;
- n 2, 3 or 4;
- n is 1, 2, 3, 4, 5, 6, 7 or 8 when X is CH 2 , or 2, 3, 4, 5, 6, 7 or 8 when X is O, S or NR 4 ;
- x is O, 1, 2 or 3;
- formula (I) is intended to embrace all possible isomers, including optical isomers, and mixtures thereof, including racemates.
- the present invention includes within its scope prodrugs of the compounds of formula (I) above.
- prodrugs will be functional derivatives of the compounds of formula (I) which are readily
- alkyl means saturated hydrocarbon having straight or branched groups, or combinations thereof.
- aryl means optionally substituted carbocyclic or heterocyclic aromatic groups, especially phenyl.
- Heteroaryl means aromatic rings preferably having 5 or 6 ring atoms and containing at least one atom selected from O, S and a group NR 5 , where R 3 is as previously defined.
- suitable cycloalkyl groups include cyclopropyl, cyclopentyl and cyclohexyl groups, preferably cyclopropyl.
- R 8 is optionally substituted aryl, this will preferably be optionally substituted phenyl.
- Suitable substituents include C 1-4 alkyl, C 1-4 alkoxy, halo and trifluoromethyl. Preferred is unsubstituted phenyl or phenyl substituted by C 1-6 alkyl, for example, phenyl substituted by C 1-6 alkyl, such as methyl, in the ortho position.
- R 8 is C 1-6 alkyl, it will preferably represent C 1-4 alkyl. Particularly preferred are methyl and iso-propyl, especially iso-propyl.
- Halo includes fluoro, chloro and bromo.
- halo will preferably be fluoro or chloro.
- R 1 represents C 1-6 alkyl, C 3-7 cycloalkyl
- R 2 represents a phenyl group optionally substituted by one or more substituents selected from C 1-4 alkyl, halo, hydroxy, OR 5 (where R 5 is as previously defined), (CH 2 ) q -tetrazolyl optionally substituted in the tetrazole ring by C 1-4 alkyl, (CH 2 ) q -imidazolyl, (CH 2 ) q -triazolyl (where q is 1, 2 or 3), 5-hydroxy-4-pyrone, NR 6 R 7 ,
- R 2 represents a group
- W represents CH 2 or NR 9
- R 9 is as previously defined
- m is 2.
- R 1a represents C 1-6 alkyl, C 3-7 cycloalkyl
- R 2a represents H, C 1-6 alkyl, halo, hydroxy, OR 5 (where R 5 is as previously defined), (CH 2 ) q a-tetrazole optionally substituted on N by C 1-4 alkyl, (CH 2 ) q a-imidazolyl, CONR 6 R 7 (where R 6 and R 7 are as previously defined), trifluoromethyl, CONHSO 2 R 8 , SO 2 NHCOR 8 (where R 8 is C 1-4 alkyl, optionally substituted aryl or
- R 3a represents H, C 1-6 alkyl or halo
- n a is 1, 2 or 3 when X is CH 2 , or 2 or 3 when X is O, S or NR 4 ;
- X is preferably o, S, CH 2 or N(C 1-4 alkyl), more preferably CH 2 or NCH 3 , especially CH 2 .
- R 1 is C 1-6 alkyl, more preferably
- C 1-4 alkyl such as methyl, ethyl, n-propyl or isobutyl.
- Suitable values for R 8 include methyl, ethyl, i-propyl, t-butyl, phenyl, o-methylphenyl and
- R 2 is phenyl substituted by SO2NHR 10
- suitable values of R 10 include, for example, thiazole, thiadiazole and pyrazine.
- q is zero.
- R 2 is phenyl substituted by methyl, ethyl, chloro, 5-hydroxy-4-pyrone, trifluoromethyl or dimethylamino; or R 2 is
- R 2 When R 2 represents monosubstituted phenyl, the substituent will preferably be located at the 3- or 4- position of the phenyl ring, more preferably the 3- position. When R 2 represents disubstituted phenyl, the substituents will preferably be located at the 3- and 4- positions. When R 2 represents a group
- the fused 5-membered ring will preferably be fused across the 3 and 4 positions of the phenyl ring.
- Suitable values for R 3 include methyl and
- x is 0 or 1, more preferably 0.
- n 2
- n is preferably 2 or 3.
- X is CH 2
- n is preferably 2, 3, 4 or 5, more preferably 3, 4 or 5, especially 3.
- homopiperidine N-methylpiperazine, heptamethyleneimine and octamethyleneimine, especially homopiperidine.
- X b represents O, S, NR 4b or CH 2 , where R 4b
- R 1b represents C 1-6 alkyl, preferably C 1-4 alkyl
- R 2b represents a phenyl group optionally substituted by one or two substitutents selected from C 1-6 alkyl, halo, hydroxy, C 1-4 alkoxy, (CH 2 )q-tetrazolyl optionally substituted in the tetrazole ring by C 1-4 alkyl, where q is 0, 1, 2 or 3, 5-hydroxy-4-pyrone, NR 6 R 7 (where R 6 and R 7 are as previously defined), NR 9 COR 5 , NR 9 CONR 9 R 5 where R 5 , R 9 and R 9' are as previously defined, CONR 6 R 7 or trifluoromethyl; or
- R 2 represents a group
- n is 1, 2, 3, 4 or 5 when X b is CH 2 , or 2, 3, 4 or 5 when X b is O, S or NR 4b ;
- R 1b is methyl, ethyl or n-propyl
- R 2b is phenyl substituted in the 3-position by methyl, ethyl or 5-hydroxy-4-pyrone, or R 2b is
- X b is CH 2 or NCH 3 , more preferably CH 2 ; and n is 3, 4 or 5 where X b is CH 2 or 2 where X is NCH 3 .
- a particularly preferred compound according to formula (Ib) is (-)-N-[2,3-dihydro-5-(homopiperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N -[3-methylphenyl]urea.
- the salts of the compounds of formula (I) are pharmaceutically acceptable, but non-pharmaceutically acceptable salts may be used for the preparation of pharmaceutically acceptable salts.
- the pharmaceutically acceptable salts of the compounds of formula (I) include the conventional non-toxic salts or the quaternary ammonium salts of the compounds from formula (I) formed, e.g., from non-toxic inorganic or organic salts.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulphuric, sulphamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, steric, lactic, malic, tartaric, citric, ascorbic, palmoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic,
- salts of the compounds according to the invention are hydrohalide, especially hydrochloride, salts.
- the salts of the present invention can be any organic compound having the same properties.
- the salts of the present invention can be any organic compound having the same properties.
- the salts are prepared by reacting the free base or acid with
- the present invention also encompasses a
- composition comprising a compound of formula (I), or a salt or prodrug thereof and a
- the compounds of formula (I) and their salts and prodrugs may be administered to animals, preferably to mammals, and most especially to a human subject either alone or, preferably, in combination with
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having pharmaceutical practice.
- the compounds can be any organic compound having
- the selected compounds may be any organic compound having the selected compounds.
- the selected compounds may be any organic compound.
- aqueous solution or suspension administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
- carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added.
- useful diluents include lactose and dried corn starch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavouring agents may be added.
- ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered.
- the total concentration of solutes should be controlled in order to render the preparation isotonic.
- a compound of formula (I) may be formulated as, for example, a suspension, lotion, cream or ointment.
- acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or arylalkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally-employed non-toxic, pharmaceutically acceptable organic and inorganic carriers.
- the pharmaceutical preparation may also contain non-toxic auxiliary substances such as
- emulsifying, preserving, wetting agents, bodying agents and the like as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetates,
- gluconate buffers and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, polyoxyethylene sorbitan monopalmitylate, dioctyl sodium sulfosuccinate, monothiojglycerol, thiosorbitol,
- the compounds of formula (I) antagonise CCK and/or gastrin and are useful for the treatment and prevention of disorders including central nervous system disorders wherein CCK and/or gastrin may be involved.
- diseases include gastrointestinal diseases, including gastrointestinal ulcers, such as peptic and duodenal ulcers, irritable bowel syndrome,
- central nervous system disorders including central nervous system disorders caused by CCK
- dopamine, serotonin and other monoamine neurotransmitters such as neuroleptic disorders, tardive dyskinesia, Parkinson's disease, psychosis or Gilles de la Tourette syndrome; depression, such as depression resulting from organic disease, secondary to stress associated with personal loss, or idiopathic depression; schizophrenia; disorders of appetite regulatory systems; Zollinger-Ellison syndrome, antral and cell hyperplasia, or pain.
- the compounds of formula (I) are particularly useful in the treatment or prevention of neurological disorders involving anxiety disorders and panic disorders, wherein CCK and/or gastrin is involved. Examples of such
- disorders include panic disorders, anxiety disorders, panic syndrome, anticipatory anxiety, phobic anxiety, panic anxiety, chronic anxiety and endogenous anxiety.
- the compounds of formula (I) are also useful for directly inducing analgesia, opiate or non-opiate mediated, as well as anesthesia or loss of the sensation of pain.
- the compounds of formula (I) may further be useful for preventing or treating the withdrawal response produced by chronic treatment or abuse of drugs or alcohol.
- drugs include, but are not limited to benzodiazepines, cocaine, alcohol and nicotine.
- the compounds of formula (I) may further by useful in the treatment of stress and its relationship with drug abuse.
- the compounds of formula (I) may further be useful in the treatment of oncologic disorders wherein CCK may be involved.
- oncologic disorders include small cell adenocarcinomas and primary tumours of the central nervous system glial and neuronal cells.
- tumours examples include, but are not limited to, tumours of the lower oesophagus, stomach, intestine, colon and lung, including small cell lung carcinoma.
- the compounds of formula (I) may also be useful as neuroprotective agents, for example, in the treatment and/or prevention of neurodegenerative disorders arising as a consequence of such pathological conditions as stroke, hypoglycaemia, cerebral palsy, transient cerebral ischaemic attack, cerebral ischaemia during cardiac pulmonary surgery or cardiac arrest, perinatal asphyxia, epilepsy, Huntington's chorea, Alzheimer's disease,
- Olivo-ponto-cerebellar atrophy anoxia such as from drowning, spinal cord and head injury, and poisoning by neurotoxins, including environmental neurotoxins.
- the compounds of formula (I) may further be used to induce miosis for therapeutic purposes after certain types of examination and intraocular surgery.
- An example of intraocular surgery would include cateract surgery with implantation of an artificial lens.
- the CCK antagonist compounds of this invention can be used to prevent miosis occuring in association with crizotis, ureitis and trauma.
- the present invention therefore provides a compound of formula (I) or a salt or prodrug thereof for use in the preparation of a medicament.
- the present invention also provides a compound of formula (I) for use in therapy.
- prescibing physician with the dosage generally varying according to the age, weight, and response of the
- an effective daily dosage wll be in the range from about 0.005mg/kg to about 100mg/kg of body weight, and
- 0.05mg/kg to about 50mg/kg such as from about 0.5mg/kg to about 20mg/kg of body weight, administered in single or divided doses.
- dosages outside these limits.
- animal experiments have indicated that doses as low as lng may be effective.
- preferably about 0.05 mg/kg to about 0.5 mg/kg of CCK antagonist may be administered orally (p.o.), administered in single or divided doses per day (b.i.d.).
- Other routes of administration preferably about 0.05 mg/kg to about 0.5 mg/kg of CCK antagonist may be administered orally (p.o.), administered in single or divided doses per day (b.i.d.).
- Other routes of administration preferably about 0.05 mg/kg to about 0.5 mg/kg of CCK antagonist may be administered orally (p.o.), administered in single or divided doses per day (b.i.d.).
- the effective dosage preferably ranges from about 100 ng/kg to about 1mg/kg by systemic
- Oral administration is an alternative route, as well as others.
- CCK antagonist In the treatment or irritable bowel syndrome, preferably about 0.1 to 10 mg/kg of CCK antagonist is administered orally (p.o.), administered in single or divided doses per day (b.i.d.).
- Other routes of administration preferably about 0.1 to 10 mg/kg of CCK antagonist is administered orally (p.o.), administered in single or divided doses per day (b.i.d.).
- an effective dosage of preferably about 0.1 to about 10 mg/kg administered oneto-four times daily is indicated.
- the effective dosage preferably ranges from about 0.5mg/kg to about 20mg/kg.
- these compounds may also be used as feed additives to increase the food intake of animals in daily dosage of preferably about 0.05mg/kg to about 50mg/kg of body weight.
- the compounds of formula (I) may be prepared by reacting intermediates of formula (II) with compounds of formula (III)
- reaction is conveniently effected in a suitable organic solvent, such as an ether, for example,
- R 1 , R 3 , X, m, n and x are as defined for formula
- Suitable hydrogenation catalysts include, for example, noble metal catalysts, e.g. ruthenium, or rhodium which may be supported, for example, on carbon.
- the reaction is preferably conducted in a suitable organic solvent, such as an alcohol, for example,
- methanol at elevated temperature, such as about 60 to 70oC, preferably about 60°C.
- Suitable reduction methods using metals include, for example, the use of zinc and trifluoroacetic acid in a suitable solvent, such as acetic acid, preferably at elevated temperature, e.g. at about 40°C.
- R 1 , R 3 , X, m, n and x are as defined for formula (I) and R 50 represents alkyl, by reduction, for example, by catalytic hydrogenation.
- Suitable hydrogenataion catalysts include, for example, noble metal catalysts, such as palladium, which may be supported, for example, on carbon.
- reaction is conveniently conducted in a suitable organic solvent, such as an alcohol, for example, methanol, suitably at ambient temperature.
- a suitable organic solvent such as an alcohol, for example, methanol
- a base such as a tertiary amine, for example, triethylamine.
- the reaction is conveniently effected in a suitable organic solvent at low temperature, such as about 0°C.
- reaction is conveniently effected in a suitable organic solvent, such an ether, for example,
- tetrahydrofuran suitably at elevated temperature, such as about 60°C.
- R 1 , R 3 , X, m, n and x are as defined for formula (I), by reaction with isoamyl nitrite in the presence of a base.
- Suitable bases of use in the reaction include alkali metal alkoxides, such as potassium t-butoxide.
- R 1 , R 3 and x are as defined for formula (I) and Hal represents halo, such as chloro, by reaction with a compound of formula (VIII)
- R 1 , R 3 and x are as defined for formula (I), by treatment with a halogenating agent, such as a phosphorus pentahalide, for example, phosphorus pentachloride.
- a halogenating agent such as a phosphorus pentahalide, for example, phosphorus pentachloride.
- reaction is conveniently effected in a suitable organic solvent, such as a halogenated hydrocarbon, for example, dichloromethane.
- a suitable organic solvent such as a halogenated hydrocarbon, for example, dichloromethane.
- R 1 , R 3 and x are as previously defined, by treatment with glycine and acetic acid at elevated temperature.
- R 1 , R 3 and x are as previously defined, Hal represents halo, such as bromo, and R 29 represents
- reaction is conveniently effected in a suitable organic solvent, such as an alcohol, e.g. methanol.
- a suitable organic solvent such as an alcohol, e.g. methanol.
- R 1 , R 3 , R 29 and x are as previously defined, by treatment with a reagent of formula Hal-CH 2 -CO-Hal, wherein Hal is as previously defined.
- reaction is conveniently effected in a suitable organic solvent, such as a halogenated hydrocarbon, e.g. dichloromethane.
- a suitable organic solvent such as a halogenated hydrocarbon, e.g. dichloromethane.
- the present invention therefore provides
- novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the novel compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-L-tartaric acid and/or (+)-di-p-toluoyl-D-tartaric acid followed by fractional crystallization and regeneration of the free base.
- the novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
- enantiomers of the novel compounds may be separated by HPLC using a chiral column.
- protecting groups may be removed at a convenient
- EXAMPLE 1 N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5- (piperidin-1-yl)-1H-1,4-benzodiazepin-3-yl] N , -[3-methylphenyl] .urea.
- Step A Methyl 2- (N-bromoacetyl-N-methylamino)benzoate Sodium, hydroxide solution (1.5 M, 50 ml) was added dropwise to an ice cooled mixture of bromoacetyl bromide (11g) and methyl N-methylanthranilate (8.2 g) in dichloromethane (250 ml). After the addition was complete (15 min) stirring was continued at room temperature for 20 min. The organic phase was then separated, washed with IN HCl (50 ml), brine (50 ml), NaHCO 3 solution (50 ml), dried (MgSO 4 ) and evaporated to give a colourless oil which crystallised on standing.
- Step B 1-Methyl-1,2,3,4-tetrahydro-3H-1,4 benzodiazepin-2,5-dione
- Step C 5-Chloro- 1 ,2-dihydro- 1-methyl-3H- 1 ,4-benzodiazepin-2-one hydrochloride
- Step D 1,2-Dihydro-1-methyl-5-(piperidin-1-yl)-3H-1,4- benzodiazepin-2-one
- Potassium t-butoxide (0.65g) was added portionwise to a solution of 1,2 dihydro-1-methyl-5-(piperidin-1-yl)-3H-1,4-benzodiazepin-2-one (0.55g) in dry toluene (50ml) cooled below -10°, under nitrogen. After 15 min isoamyl nitrite (0.33ml) was added to one portion and stirring continued for 25 min. Citric acid (1M, 20ml) was then added and the mixture extracted with ethyl acetate (4 ⁇ 50ml).
- Step F 3-Amino-1,2-dihydro-1-methyl-5-(piperidin-1-yl)-3H-1,4-benzodiazepin-2-one
- Step G N-[3(R,S)-2,3 Dihydro-1-methyl-2-oxo-5-piperidin-1-yl)-1H-1,4-benzodiazepin-3-yI]N'-(3-methylphenyl) urea
- m-Tolyl isocyanate (0.025g) was added in one portion to a solution of 3-am-mo-1,2-dihydro-1-methyl-5-(piperidin-1-yl)-3H-1,4-benzodiazepin-2-one (0.03g) in THF (1ml) at room temperature. After 5 min a solid precipitated which as collected by centrifugation to afford 0.03g of product as a colourless powder. mp 241-5°.
- Steps 1A-G whilst replacing piperidine in Step 1D with N-methylpiperazine and m-tolyl isocyanate in Step 1G with 3-ethylphenyl isocyanate afforded the titled compound as a colourless powder, mp 218-9°C.
- Step 1G Carrying out Steps 1A-G whilst replacing piperidine in Step ID with N-methylpiperazine and m-tolyl isocyanate in Step 1g with p-tolyl isocyanate afforded the titled compound as a colourless powder, mp, dec>240° (EtOH).
- EXAMPLE 7 N-[3( R,S)-2,3-Dihydro- 1-methyl-5-(4-methylpiperazin-1-yl-2-oxo-1H-1,4-benzodiazepin-3-yl] N'-[4-chlorophenvn urea.
- Step B 1-Propyl-1,2,3,4-tetrahydro-3H-1,4-benzodiazepin-2,5-dione
- Step C N-[3(R,S)-2,3-Dihydro-5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step A N-[3(R,S)-5-(4-t-Butyloxycarbonylpiperazin-1-yl)- 2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step B N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(piperazin- 1-yl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step A 3-Amino- 1, 2-dihydro- 1-methyl-5-(4-methylpiperazin-1-yl)-3H- 1,4-benzodiazepin-2-one Trifluoroacetate
- Example 4 1,2-Dihydro-1-methyl-5-(4-methylpiperazin-1-yl)-3-oximido-3H-1,4-benzodiazepin-2-one (Example 4, prepared using the procedure described in Example 1, 250mg) was dissolved in glacial acetic acid (10ml). Trifluoroacetic acid (0.13ml) was added and the solution warmed to 40°C. Zinc granules (130mg) were added and the mixture was stirred at 40°C for 5 hours. The mixture was cooled, evaporated to dryness and azeotroped with toluene to afford the crude amine trifluoroacetate salt, which was used in the next step.
- Step B N-[3 ( R , S )- 2 , 3-Dihydro - 1-methyl-5-(4-methylpiperazin-1-yl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N-[3-methoxyphenyl] urea
- Step A 3-Amino-1,2-dihydro-5-(4-methylpiperazin-1-yl)-1-propyl-3H-1,4-benzodiazepin-2-one Acetate
- 1,2-Dihydro-5-(4-methylpiperazin-1-yl)-3-oximido-1-propyl-3H-1,4-benzodiazepin-2-one (Example 8, prepared using the procedure described in Example 1, 120mg) was hydrogenated at 40 psi in methanol (50ml), containing glacial acetic acid (21 ⁇ L), at 60°C over 5% rhodium on carbon (112mg) for 3 hours. The reaction mixture was filtered and evaporated to dryness to afford the crude amine acetate salt which was used in the next step.
- Step B N-[3(R,S)-2,3-Dihydro-5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[3-methoxyphenyl] urea
- Step B l-Methyl-5-(3-nitrophenyl)tetrazole and 2-methyl-5-(3-nitrophenyl)tetrazole
- Step D N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(4-methylpiperazin-1-yl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(2-methyltetrazol-5-yl)phenyl] urea
- Triphosgene (237mg) was added to a stirred, cooled (4°C) solution of 5-(3-Aminophenyl)-2-methyltetrazole (418mg) in anhydrous tetrahydrofuran (10ml).
- Triethylamine 333 ⁇ l was added, the cooling bath was removed and the reaction mixture stirred at room temperature for 40 minutes.
- a solution of 3-amino-1,2-dihydro-1-methyl-5-(4-methylpiperazin-1-yl)-3H-1,4-benzodiazepin-2-one (Example 4, 572mg) in anhydrous tetrahydrofuran (10ml) was added then the reaction mixture was stirred for 3 hours.
- Step B N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(4-methylpiperazin-1-yl)-1H-1,4-benzodiazepin-3-yl)-N'-[3-(1-methyltetrazol-5-yl)phenyl] urea
- Triphosgene (122mg) was added to a stirred, cooled (4°C) solution of 5-(3-aminophenyl)-1-methyltetrazole (220mg) in anhydrous tetrahydrofuran (10ml).
- Triethylamine (0.175ml) was added and the mixture was stirred at 4°C for 20 minutes.
- 3-Amino-1,2-dihydro-1-methyl-5-(4-methylpiperazin-1-yl)-3H- 1,4-benzodiazepin-2-one trifluoroacetate (Example 10, 650mg crude) was suspended in anhydrous tetrahydrofuran (10ml).
- N,N-Dimethyl-3-nitrophenylcarboxamide (6.00g) was hydrogenated at 40 psi in ethanol (150ml) using 10% palladium on carbon (0.60g) for 30 minutes. The reaction mixture was filtered, evaporated to give a colourless solid (5.05g), mp 86-87°C. R f 0.22 in ethyl acetate on silica. Found: C, 66.06; H, 7.26; N, 17.28. C 9 H 12 N 2 O requires C, 65.83; H, 7.37; N, 17.06%.
- Step C N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(4-methylpiperazin-1-yl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(N,N- dimethylcarboxamido)phenyl] urea
- Step A N-[3(R,S)-5-(4-t-Butyloxycarbonylhomopiperazin-1-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step B N-[3(R,S)-2,3-Dihydro-5-(homopiperazin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- N-Ethyl-3-nitrophenylcarboxamide (7.0g) was hydrogenated at 40 psi in ethanol (180ml) using 10% palladium on carbon
- Step C N-[3(R,S)-2,3-Dihvdro-1-methyl-2-oxo-5-(4-methylpiperazin-1-yl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(N- ethylcarboxamido)phenyl] urea
- Step A 3-Amino-1,2-dihydro-1-methyl-5-(piperidin-1-yl)-3H- 1,4-benzodiazepin-2-one
- Step B N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(piperidin-)
- Step A 1,2-Dihydro-5-(homopiperidin-1-yl)-1-methyl-3-oximido-3H-1,4-bepzodiazepin-2-one
- Steps 1A-1E Carrying out Steps 1A-1E whilst replacing piperidine in Step ID with homopiperidine afforded the title compound as a cream solid (0.77g). mp 210-212°C (ethyl acetate/diethyl ether).
- Step C N-[3(-R,S)-2,3-Dihydro-5-(homopiperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step B 1-(2-Methylpropyl-1,2,3,4-tetrahydro-3H-1,4-benzodiazepin-2,5-dione
- Step D N-[3(R,S)-2,3-Dihydro-5-(4-methylpiperazin-1-yl)-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step A 3-Amino - 1,2- dihydro- 1-methyl- 5-(4-methylpiperazin-1-yl)-3H-1,4-benzodiazepin-2-oneTrifluoroacetate
- Example 4 1,2-Dihydro-1-methyl-5-(4-methylpiperazin-1-yl)-3-oxi ⁇ nido-3H-1,4-benzodiazepin-2-one (Example 4, prepared using the procedure described in Example 1, 320mg) was dissolved in glacial acetic acid (10ml). Trifluoroacetic acid (0.16ml) was added and the solution warmed to 40°C. Activated zinc powder (Fieser and Fieser, 1967, Volume 1, 1276, 166mg, 2.54mmol) was added and the mixture was stirred at 40°C for 3 hours. The mixture was cooled, evaporated to dryness and azeotroped with toluene to afford the crude amine trifluoroacetate salt, which was used in the next step.
- Trifluoroacetic acid (0.16ml) was added and the solution warmed to 40°C.
- Activated zinc powder (Fieser and Fieser, 1967, Volume 1, 1276, 166mg, 2.54mmol
- Step B N-[3(R,S)-2,3-Dihydro-1-methyl-2-oxo-5-(4-methylpiperazin-1-yl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-trifluoromethylphenyl] urea
- Step A 3-Amino-1,2-dihydro-5-(4-methylpiperazin-1-yl)-1- propyl-3H-1,4-benzodiazepin-2-one Trifluoroacetate
- 1,2-Dihydro-5-(4-methylpiperazin-1-yl)-3-oximido-1-propyl-3H-1,4-benzodiazepin-2-one (410mg) was dissolved in glacial acetic acid (10ml). Trifluoroacetic acid (0.67ml) was added and the solution warmed to 40°C. Activated zinc powder (Fieser and Fieser, 1967, Volume 1, 1276, 567mg) was added and the mixture was stirred at 40°C for 10 hours. The mixture was cooled, filtered then evaporated to dryness and azeotroped with toluene to afford the crude amine trifluoroacetate salt, which was used in the next step.
- Step B N-[3(R,S)-2,3-Dihydro-5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-1H- 1 4 -benzodiazepin- 3-yl] -N'-[ 3-trifluoromethylphenyl] urea
- Step A 3-Amino-1,2-dihydro-5-(4-methylpiperazin-1-yl)-1-propyl-3H-1,4-benzodiazepin-2-one Trifluoroacetate
- Step B N-[3(R,S)-2.3-Dihydro-5-(4-methylpiperazin-1-yl)-2-oxo- 1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[5-indanyl] urea
- Step A ⁇ -Amino-N-(2,3-dihydro-5-(4-methylpiperazin-1-yl)- 2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl)benzene propanamide
- 3-amino-1 ,2-dihydro-5-(4-methylpiperazin-1-yl)-1-propyl-3H-1,4-benzodiazepin-2-one (Example 33, 2.96g) in anhydrous dimethylformamide (30ml) wa s adde d B O C - D - p henyl alanine ( 2.
- the product obtained (5.28g) was treated at 0°C with ethyl acetate (100ml) saturated with hydrogen chloride gas and stirred at 0°C for 1 hour.
- the combined organics were dried (sodium sulphate) and the more polar (by silica tic) diastereomer crystallised from methanol/diethyl ether to afford a beige solid (460mg). mp 152-153°C.
- Step B (-)-N-[2,3-Dihydro-5-(4-methylpiperazin-1-yl)-2-oxo- 1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[5-indanyl] urea
- Phenyl isothiocyanate (117 ⁇ l) was added to a stirred solution of the foregoing diastereomeric amide (0.41g) in anhydrous dichloromethane (20ml) then heated at 40°C for 3 hours. The reaction mixture was evaporated and the residue purified by column chromatography on silica using dichloromethane to dichloromethane/methanol/ammonia (20:1:0.1), gradient elution, to afford the thiourea (0.53g). Trifluoroacetic acid (20ml) was added to the solid thiourea (0.53g) and the mixture was stirred at room temperature for 40 minutes.
- 3-Nitro-propen-1-ylbenzene (5.10g, 0.0313mol) was hydrogenated at 45 psi over 10% palladium on carbon (500mg) in ethanol (50ml) for 20 hours. The reaction mixture was filtered, then evaporated to dryness to give a yellow oil which was distilled under vacuum. 3-Propylaniline (3.40g) was obtained as a colourless oil. bp 120°C (0.6mmHg, Kugelrohr). Rf 0.49 in ethyl acetate/n-hexane (1:1) on silica plates.
- Step B N-[3(R,S)-2,3-Dihydro-5-(4-methylpiperazin-l-yl)-2- oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[3-propylphenyl] urea
- Step A 1,3-Dihydro-2H-5-(heptamethyleneimin-1-yl)-1-methyl-1,4-benzodiazepin-2-one
- Step B 1,3-Dihydro-2H-5-(heptamethyleneimin-1-yl)-1-methyl-3-oximido-1,4-bepzodiazepin-2-one
- Step C 3(R,S)-Amino-1,3-dihydro-2H-5-(heptamethyleneimin-1-yl)-1-methyl-1,4-benzodiazepin-2-one
- the foregoing oxime (0.50g) was hydrogenated over 5% rhodium on carbon (0.50g) in methanol (50ml) at 40 psi and 60°C for 5 hours.
- the reaction mixture was filtered, then evaporated to dryness to afford the title amine (0.47g) as a beige gum, which was used immediately in the next step.
- Step D N-[ 3(R,S)-2,3-Dihydro-5-(heptamethyleneimin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- m-Tolylisocyanate (0.20ml) was added to a cooled (4°C) solution of 3(R,S)-amino-1,3-dihydro-2H-5- (heptamethyleneimin-1-yl)-1-methyl-1,4-benzodiazepin-2-one (0.47g, 1.56mmol) in anhydrous tetrahydrofuran (8ml). After standing at 4°C for 1 hour the solution was evaporated to dryness and the residue re-dissslved in ethyl acetate (30ml) then washed with water (10ml).
- Step A 1,3-Dihydro-2H-5-(piperidin-1-yl)-1-propyl-1,4- benzodiazepin-2-one
- Example 8 The title compound was obtained from 1-pro ⁇ yl- 1,2,3,4-tetrahydro-3H-1,4-benzodiazepin-2,5-dione (Example 8) and piperidine as described in Example 43.
- the hydrochloride salt had mp 264-268°C. Found: C, 62.76; H, 7.39; N, 12.86.
- Step B N-[3(R,S)-2,3-Dihydro-2-oxo-5-(piperidin-1-yl)-1- propyl-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphepyl] urea
- Example 43 The hydrochloride salt had mp 227°C ( dichl o r o me than e/die thyl et her ) . Rf 0 . 70 in dichloromethane/methanol (9:1) on silica plates.
- Step B 1,3-Dihydro-2H-5-(4-methylpiperazin-1-yl)-8-nitro- 1-propyl-1,4-benzodiazepin-2-one
- Step C 1,3-Dihydro-8-dimethylamino-2H-5-(4-methylpiperazin-1-yl)-1-propyl-1,4-benzodiazepin-2-one
- Step D N-[3(R,S)-2,3-Dihydro-8-dimethylamino-5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- Step A 1,2-Dihydro-5-(homopiperidin-1-yl)-1-propyl-3H-1,4- benzodiazepin-2-one
- Step B 1,2-Dihydro-5-(homopiperidin-1-yl)-3-oximido-1-propyl-3H-1,4-benzodiazepin-2-one
- Step C N-(3(R,S)-2,3-Dihydro-5-(homopiperidin-1-yl)-2-oxo- 1-propyl-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- the title compound was obtained from the foregoing oxime as described in Example 19. mp 190-192°C (ethyl acetate).
- EXAMPLE 48 N-[3(R,S)-2,3-Dihydro-5-(homopiperidin-1-yl)-1-methyl-2-oxo-1H-1.4-benzodiazepin-3-yl]-N'-[3-trifluoromethylphenyl] urea
- Example 20 The title compound was obtained from 3-amino-1,2-dihydro-5-(homopiperidin-1-yl)-1-methyl-3H-1,4-benzodiazepin-2-one (Example 20) and 3-trifluoromethylphenyl isocyanate as described in Example 19. mp 127-130°C (dichloromethane/ diethyl ether). R f 0.70 in dichloromethane/ methanol (9:1) on silica plates. MS, CI + , m/z 474 for (M+H) + . Found: C, 59.79; H, 5.48; N, 14.45.
- the free base was liberated and obtained as a colourless solid (48mg).
- the hydrochloride salt had mp 182°C-184°C
- Potassium b ⁇ s(trimethylsilyl)amide (67ml of a 0.5M toluene solution) was added slowly to a stirred solution of 6-nitroindoline (5.0g) in anhydrous tetrahydrofuran (200ml) at -78°C under a nitrogen atmosphere. Iodomethane (2.09ml) was added then the reaction mixture was allowed to warm to room temperature then stirred overnight. Methanol (5ml) was added then the solution was evaporated to dryness. The residue was dissolved in diethyl ether (300ml), washed with water, saturated brine then dried (magnesium sulphate) and evaporated to dryness.
- the crude product was purified by column chromatography on silica using 10% ethyl acetate/petroleum ether (60-80) ⁇ 30% ethyl acetate/petroleum ether (60-80) and the product crystallised from diethyl ether/petroleum ether (60-80) to afford 0.9g.
- Step C N-[3(R,S)-2,3-Dihydro-5-(4-methylpiperazin-1-yl)-2-oxo-1-propyl-1H-1,4-benz ⁇ diazepin-3-yl]-N'-[1-methyl-6-indolinyl] urea
- Triphosgene (231mg) and triethylamine (0.8ml) were added to a stirred solution of 3-amino-1,2-dihydro-5-(homopiperidin-1-yl)-1-methyl-3H-1,4-benzodiazepin-2-one (Example 20, 0.6g) in anhydrous tetrahydrofuran (8ml) at 4°C. After stirring at 4°C for 30 minutes 3,4-difluoroaniline (0.26ml) was added. The cooling bath was removed and the reaction mixture was stirred at room temperature for 24 hours. The reaction mixture was evaporated to dryness then the residue partitioned between ethyl acetate and saturated sodium carbonate solution.
- the combined organics were dried (potassium carbonate) then evaporated to dryness to give a pale yellow oil which was purified by vacuum distillation (10.5g), bp 120-124°C (120mmHg), Rf 0.10 in dichloromethane/methanol (9:1) on silica plates.
- Step B N- [3 (R, S )-2 , 3 -D ihydro - 1-methyl- 5 -(octamethyleneimin-1-yl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'- [3-methylphenyl] urea
- n-Butyllithium (31.9ml of a 1M hexane solution) was added dropwi s e to a stirre d , co ol ed (- 78 °C ) s olution of hexamethyldisilazane (10.8ml) in anhydrous tetrahydrofuran (140ml).
- a solution of 2-acetoxy-1-methoxy-buten-3-one 8.0g, Chem. Ber. 1959, 92, 3009-3015
- anhydrous tetrahydrofuran 60ml
- Step B 3-Acetoxy-6-(3-aminophenyl)-4-pyrone
- Step C N-[3(R,S)-2,3-Dihydro-5-(homo ⁇ iperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-(5-acetoxy-4-pyron-2-yl)phenyl] urea
- Step D N-[3(R,S)-2,3-Dihydro-5-(homopiperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-(5-hydroxy-4- pyron-2-yl)phenyl] urea
- EXAMPLE 64 N-[3(R, S)-2,3-Dihydro-1-ethyl-5-(homopiperidin- 1-yl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea Step A: 1-Ethyl-1,2,3,4-tetrahydro-3H-1,4-benzodiazepin-2,5-dione
- N-ethyl isatoic anhydride as a tan powder (70g).
- N-Ethyl isatoic anhydride (64g), glycine (27g) and glacial acetic acid (500ml) were heated at reflux for 4 hours.
- Step B 1,2-Dihydro-1-ethyl-3H-5-(homo ⁇ iperidin-1-yl)-1,4-benzodiazepin-2-one
- the title compound was obtained (5.20g) from 1-ethyl- 1,2,3,4-tetrahydro-3H-1,4-benzodiazepin-2,5-dione, phosphorus pentachloride and homopiperidine as described in Example 43.
- mp 30-35°C ethyl acetate/n-hexane
- the hydrochloride salt had mp 195-198°C (ethyl acetate/diethyl ether).
- Step C 1,2-Dihydro-1-ethyl-3H-5-(homopiperidin-1-yl)-3-oximido-1,4-benzodiazepin-2-one
- Step D N-[3(R,S)-2,3-Dihydro-1-ethyl-5-(homopiperidin-1- yl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-methylphenyl] urea
- the racemate (470mg, Example 63) was separated into its two enantiomers using a semi-preparative dinitrobenzoylleucine Pirkle column (5 ⁇ ) [(250 ⁇ 20)mm] eluting with 5% methanol in
- Step A 1,2-Dihydro-5-(homopiperidin-1-yl)-1-methyl-3-(O-(ethylaminocarbonyl)oximido)-3H-1,4-benzodiazepin-2-one
- Step B 3(R,S)-Amino-1,2-dihydro-5-(homopiperidin-1-yl)-1-methyl-3H-1,4,benzodiazepin-2-one
- the foregoing oxime derivative (140mg) was hydrogenated at 45 psi in methanol (20ml) over 10% palladium on carbon (50mg) for 3 hours at room temperature. The mixture was filtered and the solvent evaporated to afford the amine as a beige foam (106mg, 95%) which was used immediately in the next step.
- Step C N-[3(R,S,)-2,3-Dihydro-5-(homopiperidin-1-yl)-1-methyl-2-oxo- 1H- 1 ,4-benzodiazepin-3-yl]-N'- [3 ,4- (methylenedioxy)phenyl] urea
- EXAMPLE 72 N-[3(-R,S)-2,3-Dihydro-5-(homopiperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[3-fluoro-4-methylphenyl] urea
- the compound of formula (I), cellulose, lactose and a portion of the corn starch are mixed and granulated with
- the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing
- the sodium phosphate, citric acid monohydrate and sodium chloride are dissolved in a portion of the water.
- the compound of formula (I) is dissolved or suspended in the solution and made up to volume.
- the white soft paraffin is heated until molten.
- the liquid paraffin and emulsifying wax are incorporated and stirred until dissolved.
- the compound of formula (I) is added and stirring continued until dispersed. The mixture is then cooled until solid.
- CCK-8 sulphated was radiolabelled with 125 I-Bolton Hunter reagent (2000 Ci/mmole). Receptor binding was performed. according to Chang and Lotti (Proc. Natl. Acad. Sci. 83, 4923-4926, 1986) with minor modifications.
- Pellets were resuspended in 10 volumes of binding assay buffer (20mM (HEPES)), 1mM ethylene glycol-bis-( ⁇ -aminoethylether-N,N'-tetraacetic acid) (EGTA), 5mM MgCl 2 , 150 mM NaCl, bacitracin 0.25 mg/ml, soya bean trypsin inhibitor 0.1 mg/ml, and bovine serum albumin 2 mg/ml pH 6.5 at 25°C) using a Teflon (trademark) homogenizer, 15 strokes at 500 rpm. The homogenate was further diluted in binding assay buffer to give a final concentration of 0.5 mg original wet weight/1 ml buffer.
- HEPES ethylene glycol-bis-( ⁇ -aminoethylether-N,N'-tetraacetic acid)
- EGTA ethylene glycol-bis-( ⁇ -aminoethylether-N,N'-tetra
- CCK-8 sulphated was radiolabelled and the binding was performed according to the description for the pancreas method with minor modifications.
- the preferred compounds of Formula I are those which produced dose-dependent inhibition of specific 125 I-CCK-8 binding as defined as the difference between total and non-specific (i.e. in the presence of 1 ⁇ M CCK) binding.
- IC 50 refers to the concentration of the compound required to inhibit 50% of specific binding of 125 I-CCK-8.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention se rapporte à des composés de la formule (I), et à des sels et promédicaments de ceux-ci, dans laquelle X représente O, S, NR4 ou CH2; R1 représente H, certain alkyle C1-6 ou cycloalkyle C3-7 éventuellement substitué; R2 représente phényle possédant certains éventuels substituants; R3 représente alkyle C1-6, halo ou NR6R7; m est 2, 3 ou 4; n est 1, 2, 3, 4, 5, 6, 7 ou 8 lorsque X représente CH2 ou 2, 3, 4, 5, 6, 7 ou 8 lorsque X représente O, S ou NR4; et x est 0, 1, 2, 3 ou 4; ces dérivés étant des antagonistes de CCK et/ou gastrine. Ils sont utilisés ainsi que leurs compositions en thérapie.The invention relates to compounds of formula (I), and to salts and prodrugs thereof, wherein X represents O, S, NR4 or CH2; R1 represents H, certain C1-6 alkyl or optionally substituted C3-7 cycloalkyl; R2 represents phenyl having certain optional substituents; R3 represents C1-6 alkyl, halo or NR6R7; m is 2, 3 or 4; n is 1, 2, 3, 4, 5, 6, 7 or 8 when X represents CH2 or 2, 3, 4, 5, 6, 7 or 8 when X represents O, S or NR4; and x is 0, 1, 2, 3 or 4; these derivatives being CCK and / or gastrin antagonists. They are used as well as their compositions in therapy.
Description
Claims
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9122634 | 1991-10-24 | ||
GB919122634A GB9122634D0 (en) | 1991-10-24 | 1991-10-24 | Therapeutic agents |
GB9203085 | 1992-02-13 | ||
GB929203085A GB9203085D0 (en) | 1992-02-13 | 1992-02-13 | Therapeutic agents |
GB929208107A GB9208107D0 (en) | 1992-04-13 | 1992-04-13 | Therapeutic agents |
GB9208107 | 1992-04-13 | ||
GB9214544 | 1992-07-08 | ||
GB929214544A GB9214544D0 (en) | 1992-07-08 | 1992-07-08 | Therapeutic agents |
PCT/GB1992/001936 WO1993008176A1 (en) | 1991-10-24 | 1992-10-21 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0609306A1 true EP0609306A1 (en) | 1994-08-10 |
Family
ID=27450763
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92309589A Ceased EP0539170A1 (en) | 1991-10-24 | 1992-10-21 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
EP92921626A Withdrawn EP0609306A1 (en) | 1991-10-24 | 1992-10-21 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92309589A Ceased EP0539170A1 (en) | 1991-10-24 | 1992-10-21 | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
Country Status (6)
Country | Link |
---|---|
EP (2) | EP0539170A1 (en) |
JP (1) | JPH07500589A (en) |
AU (1) | AU667690B2 (en) |
CA (1) | CA2119875A1 (en) |
IL (1) | IL103502A0 (en) |
WO (1) | WO1993008176A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0652873A1 (en) * | 1992-07-29 | 1995-05-17 | MERCK SHARP & DOHME LTD. | Benzodiazepine derivatives |
AU671477B2 (en) * | 1992-07-29 | 1996-08-29 | Merck Sharp & Dohme Limited | Benzodiazepine derivatives |
US5438055A (en) * | 1993-11-22 | 1995-08-01 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
WO1996005827A1 (en) * | 1994-08-18 | 1996-02-29 | Merck & Co., Inc. | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
US5426185A (en) * | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
US5428157A (en) * | 1993-11-22 | 1995-06-27 | Merck & Co., Inc. | 3-acylaminobenzodiazepines |
EP0755394A1 (en) * | 1994-04-15 | 1997-01-29 | Glaxo Wellcome Inc. | A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds |
HU220635B1 (en) * | 1994-08-18 | 2002-03-28 | Merck & Co. Inc. | 2,3-dihydro-1-(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines, pharmaceutical compositions containing them and their use for preparation of pharmaceutical compositions |
US5726171A (en) * | 1995-06-07 | 1998-03-10 | Merck & Co Inc | N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo B! 1,4!diazepin-3yl)-acetamides |
US5691331A (en) * | 1995-06-07 | 1997-11-25 | Merck & Co., Inc. | N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides |
US5700797A (en) * | 1995-06-07 | 1997-12-23 | Merck & Co, Inc. | N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides |
WO1996040656A1 (en) * | 1995-06-07 | 1996-12-19 | Merck & Co., Inc. | Novel n-(2,4-dioxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3yl)-3-amides |
US5631251A (en) * | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
MX9802383A (en) * | 1995-10-02 | 1998-08-30 | Hoffmann La Roche | Pyrimidine derivatives as 5ht2c-receptor antagonists. |
US5929071A (en) * | 1996-07-02 | 1999-07-27 | Merck & Co., Inc. | Method for the treatment of preterm labor |
WO1998000406A1 (en) * | 1996-07-02 | 1998-01-08 | Merck & Co., Inc. | Method for the treatment of preterm labor |
WO2000037434A1 (en) * | 1998-12-22 | 2000-06-29 | Mitsubishi Chemical Corporation | Amide derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2032226A1 (en) * | 1989-12-18 | 1991-06-19 | Mark G. Bock | Benzodiazepine analogs |
IL96613A0 (en) * | 1989-12-18 | 1991-09-16 | Merck & Co Inc | Pharmaceutical compositions containing benzodiazepine analogs |
GB9203790D0 (en) * | 1992-02-21 | 1992-04-08 | Merck Sharp & Dohme | Therapeutic agents |
IL104853A (en) * | 1992-02-27 | 1997-11-20 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them |
CA2130196A1 (en) * | 1992-03-24 | 1993-09-30 | Jose Luis Castro Pineiro | Benzodiazepine derivatives |
-
1992
- 1992-10-21 AU AU27887/92A patent/AU667690B2/en not_active Ceased
- 1992-10-21 EP EP92309589A patent/EP0539170A1/en not_active Ceased
- 1992-10-21 EP EP92921626A patent/EP0609306A1/en not_active Withdrawn
- 1992-10-21 JP JP5507565A patent/JPH07500589A/en active Pending
- 1992-10-21 WO PCT/GB1992/001936 patent/WO1993008176A1/en not_active Application Discontinuation
- 1992-10-21 CA CA002119875A patent/CA2119875A1/en not_active Abandoned
- 1992-10-21 IL IL103502A patent/IL103502A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9308176A1 * |
Also Published As
Publication number | Publication date |
---|---|
IL103502A0 (en) | 1993-03-15 |
AU2788792A (en) | 1993-05-21 |
CA2119875A1 (en) | 1993-04-29 |
WO1993008176A1 (en) | 1993-04-29 |
EP0539170A1 (en) | 1993-04-28 |
AU667690B2 (en) | 1996-04-04 |
JPH07500589A (en) | 1995-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU670939B2 (en) | Benzodiazepine derivatives, compositions containing them and their use in therapy | |
US5681833A (en) | Benzodiazepine derivatives | |
US5556969A (en) | Benzodiazepine derivatives | |
US5618812A (en) | Benzodiazepine derivatives | |
US5360802A (en) | Benzodiazepine derivatives, compositions containing them and their use in therapy | |
US5410049A (en) | Benzodiazepine derivatives, compositions containing them and their use in therapy | |
US5451582A (en) | Benzodiazepine derivatives, compositions containing them and their use in therapy | |
AU667690B2 (en) | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors | |
EP0514133A1 (en) | Benzodiazepine derivatives, compositions containing them and their use in therapy | |
US5302591A (en) | Benzodiazepine derivatives | |
US5478933A (en) | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors | |
AU671141B2 (en) | Benzodiazepine derivatives | |
US5602125A (en) | Thienodiazepine derivatives as cholecystokinin and gastrin antagonists | |
EP0595980A1 (en) | Benzodiazepine derivatives, compositions containing them and their use in therapy | |
CA2066083C (en) | Benzodiazepine analogs as cholecystokinin antagonists | |
US5696110A (en) | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors | |
US5620972A (en) | Substituted benzene derivatives | |
GB2271991A (en) | N-(2-oxo-1H-1,4-benzodiazepin-3-yl)-ureas | |
GB2266528A (en) | Benzodiazepine derivatives | |
GB2271354A (en) | Tricyclic derivatives of benzodiazepines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19940225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19970422 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990223 |